Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07122453
PHASE1

Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain

Sponsor: Centrexion Therapeutics

View on ClinicalTrials.gov

Summary

This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001. This Phase 1 study is the first time that CNTX-3001 will be given to people (first-in-human study). The study is being done to evaluate whether CNTX-3001, given into the intrathecal space by lumbar puncture, can be administered safely to participants who have been diagnosed with intractable chronic moderate to severe low back pain and who have not responded well to other treatments in the past. CNTX-3001 is a novel, non-opioid small molecule

Official title: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Single Ascending Doses of Intrathecal CNTX-3001 in Subjects With Intractable Chronic Moderate to Severe Low Back Pain

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2026-03

Completion Date

2027-01

Last Updated

2026-03-23

Healthy Volunteers

No

Conditions

Interventions

DRUG

CNTX-3001

non-opioid analgesic

DRUG

Placebo

Placebo product

Locations (1)

Neurovations

Napa, California, United States